Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
The capacity of interleukin 12 (IL-12) to potentiate drugs in the treatment of murine toxoplasmosis was examined. IL-12 (100 ng/injection), atovaquone (10 mg/kg of body weight/day), or clindamycin (5 mg/kg/day) administered alone caused delayed time to death or minimal survival rates. In contrast, s...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1997
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163683/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8980778/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.41.1.188 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|